EU Clinical Trial 2017-003344-21

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)  May 27, 2019

Main objective of the trial: To compare the overall survival (OS) of subjects with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of subjects treated with chemotherapy

Parties

Sponsors
Countries
AR AT AU BE BR CA CH DE DK ES EU FR GB IE IT JP KR NL PT RU TW US
Keywords
78991.00.00 ASG-22CE DOCETAXEL Docetaxel Amneal Pharma Europe Docetaxel amneal 20mg/ml Docetaxel cell pharm 20 mg/ml ENFORTUMAB VEDOTIN Enfortumab Vedotin Javlor 25mg/mL PACLITAXEL Paclitaxel 6 mg/mL Paclitaxel Amneal 6 mg/ml Urothelial carcinoma bladder VINFLUNINE

JSON preview

Similar records

Title